HEPATITIS C AND NONALCOHOLIC FATTY LIVER DISEASE IN HIV INFECTED PATIENTS
https://doi.org/10.22328/2077-9828-2017-9-1-36-42
Abstract
Nonalcoholic fatty liver disease (NAFL) is the main cause of chronic liver pathologies in westernized countries. The prevalence of fatty hepatosis in HIV patients is about 30% and reaches 40–72% in HIV patients co-infected with HCV, depending on other risk factors, such as NRTI and PI use in ART. Therefore, NAFL diagnostics is warranted in patients with HV/HCV co-infection. Besides that, for patients having HIV, HCV and NAFL special therapeutic approaches are required to ensure body mass reduction, HCV treatment, and drug therapy for NAFL.
About the Authors
K. V. Zhdanov
Military Medical Academy named after S.M.Kirov
Russian Federation
Russian Federation
Saint-Petersburg
K. V. Kozlov
Military Medical Academy named after S.M.Kirov
Russian Federation
Russian Federation
Saint-Petersburg
V. S. Sukachev
Military Medical Academy named after S.M.Kirov
Russian Federation
Russian Federation
Saint-Petersburg
References
1. Byrne C.D. NAFLD: A multisystem disease. J. Hepatol., 2016, Vol. 62, No. 1, pp. 47–64.
2. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 2016, Vol. 64, No. 6, рр. 1388–1402, doi:10.1016/j.jhep.2015.11.004.
3. Asselah T., Rubbia-Brandt L., Marcellin P., Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut., 2006, Vol. 55, рр. 123–130.
4. Price J.C. Liver Disease in the HIV-Infected Individual. Clin. Gastroenterol. Hepatol., 2010, Vol. 8 (12), рр. 1002–1012.
5. Crum-Cianflone N., Dilay A., Collins G., Asher D., Campin R., Medina S., Goodman Z., Parker R., Lifson A., Capozza T., Bavaro M., Hale B., Hames C. Nonalcoholic Fatty Liver Disease (NAFLD) among HIV-Infected Persons. J. Acquir. Immune Defic. Syndr., 2009, Vol. 50 (5), рр. 464–473, doi: 10.1097/QAI.0b013e318198a88a.
6. Guaraldi G., Squillace N., Stentarelli C., Orlando G., D’Amico R., Ligabue G. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic сlinic: prevalence, characteristics, and predictors. HIV/AIDS, 2008, Vol. 47, рр. 250–257.
7. Soriano V., Barreiro P., Sherman K.E. The Changing Epidemiology of Liver Disease in HIV Patients. AIDS Rev., 2013, Vol. 15, рр. 25–31.
8. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest., 2004, Vol. 114, No. 2, рр. 147–152.
9. Pinzani M. Fatty Liver Disease: co-factor of HCV and evolving disease entity [Internet]. Available from: http://congress-ph.ru/common/htdocs/upload/fm/gepatology/2016/prez/2-1-1.pdf.
10. Wang X., Liu Z., Wang K., Wang Z., Sun X., Zhong L., Deng G., Song G., Sun B., Peng Z., Liu W. Additive Effects of the Risk Alleles of PNPLA3 and TM6SF2 on Non-alcoholic Fatty Liver Disease (NAFLD) in a Chinese Population. Front. Genet., 2016, Vol. 7, рр. 140, doi: 10.3389/fgene.2016.00140.
11. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol., 2015, Vol. 63, рр. 237–264.
12. Жданов К.В., Гусев Д.А., Козлов К.В., Шишкин М.К., Сукачев В.С., Шахманов Д.М., Жабров С.С. Эффективность и безопасность противовирусной терапии военнослужащих, больных хроническим гепатитом С // Военно-медицинский журнал. 2015. Т. 336, № 4. С. 44–49. [Zhdanov K.V., Gusev D.A., Kozlov K.V., Shishkin M.K., Sukachev V.S., Shakhmanov D.M., Zhabrov S.S. Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C. Military-medical Journal, 2015, Vol. 336, No. 4, рр. 44–49 (In Russ.)].
13. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M. Pioglitazone, Vitamin E or placebo for NASH. New Engl. J. Med., 2010, Vol. 362, рр. 1675–1685.
14. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., Chalasani N., Dasarathy S., Diehl A.M., Hameed B., Kowdley K.V., McCullough A. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet, 2015, Vol. 385 (9972), рр. 956–965.
15. Ratziu V., Harrison S.A., Francque S., Bedossa P., Lehert P., Serfaty L. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology, 2016, Vol. 150, рр. 1147–1159.
16. http://clinicaloptions.com.
17. Таланцева М.С., Жданов К.В., Шустов С.Б., Барсуков А.В., Козлов К.В., Свеклина Т.С. Особенности суточного профиля артериального давления у больных артериальной гипертензией в сочетании с хроническим вирусным гепатитом С // Артериальная гипертензия. 2012. Т. 18, № 1. С. 61–65. [Talanceva M.S., Zhdanov K.V., Shustov S.B., Barsukov A.V., Kozlov K.V., Sveklina T.S., Arterial Hypertensia, 2012, vol. 18, No. 1, рр. 61–65. (In Russ.)].
Review
For citations:
Zhdanov K.V., Kozlov K.V., Sukachev V.S. HEPATITIS C AND NONALCOHOLIC FATTY LIVER DISEASE IN HIV INFECTED PATIENTS. HIV Infection and Immunosuppressive Disorders. 2017;9(1):36-42. (In Russ.) https://doi.org/10.22328/2077-9828-2017-9-1-36-42
Views:
1955
.png)
Email this article 